CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 6, 2004--Alkermes, Inc., (Nasdaq: ALKS) will host a conference call at 4:30pm EDT on Thursday, May 13, 2004 to discuss the Company's financial results for the fiscal year ended March 31, 2004. Management will review the year and provide an update on the Company.
The conference call may be accessed by dialing 1-866-238-0637 for domestic callers and 1-703-639-1156 for international callers. The conference call ID number is 459163. Additionally, the call will be webcast on the investor relations section of Alkermes' website at www.alkermes.com and archived on the site until Tuesday, May 18, 2004 at 5:00pm EDT.
A replay of the conference call will be available from 7:30pm EDT on May 13, 2004 through 5:00pm EDT on May 18, 2004, and may be accessed by visiting Alkermes' website or by dialing 1-888-266-2081 for domestic callers and 1-703-925-2533 for international callers. The replay access code is 459163.
Alkermes, Inc. is an emerging pharmaceutical company developing products based on its sophisticated drug delivery technologies to enhance therapeutic outcomes. Our areas of focus include: controlled, extended-release of injectable drugs utilizing our ProLease(R) and Medisorb(R) delivery systems and the development of inhaled pharmaceutical products based on our AIR(R) pulmonary delivery system. Our business strategy is twofold. We partner our proprietary technology systems and drug delivery expertise with many of the world's finest pharmaceutical companies and also develop novel, proprietary drug candidates for our own account. In addition to our Cambridge, Massachusetts headquarters, research and manufacturing facilities, we operate research and manufacturing facilities in Ohio.
CONTACT: Alkermes, Inc.
Rebecca Peterson, 617-583-6378
SOURCE: Alkermes, Inc.